Regulators will have their work cut out for them under a new administration that has expressed an anti-regulatory preference. Republicans next year will control the White House, Senate and House. What will it all mean for pharmacy leaders?
Experts agree that the incoming Trump administration will likely shake things up in the prescription drug world — most notably when it comes to research and development, drug pricing and PBM reform.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
For those who rely on these treatments, affordable medication access is a matter of health, freedom, and dignity, and their mechanisms and outcomes are non-partisan.
The biopharmaceutical industry clearly isn’t going anywhere, but we’ve been in a downward business cycle. We've learned a lot from the pandemic and have adopted novel approaches to development and this current economic challenge will also inform us. In the meantime, adopting these strategies can de-risk your development programs.
Despite these wins for many patients, the new law is already impacting the discovery and development of new drugs for people living with orphan diseases. Not only are drugs that could treat more than one disease being disincentivized, small molecule medicines, which play an important role in treating neurological disorders, cancers, and other diseases, may also be disadvantaged by the law.
Companies who raised drug prices higher than the rate of inflation must rebate the difference to Medicare, according to a provision of the Inflation Reduction Act. The highest-profile product on the list might be AbbVie’s blockbuster immunology drug Humira.
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.
President Biden continues to center his pre-midterm speeches around the issue of prescription drug costs, with two recent West Coast talks highlighting how Democrats will continue to work to lower costs for seniors. At a community center in Portland, Oregon on Saturday, three weeks ahead of the midterms, the President described an executive order he’d […]
The Act left out individuals who are covered by private insurance, and left pharmacy benefit managers, who negotiate drug prices, off the hook.